Search
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigational[A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … [A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the
Synonyms: N-Hydroxyurea, N-CarbamoylhydroxylamineVorinostat
go.drugbank.com/drugs/DB02546ApprovedInvestigationalIt is the first in a new class of agents known as histone deacetylase inhibitors. … A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier
Pyrantel
go.drugbank.com/drugs/DB11156ApprovedVet approvedIn humans, it is administered as pyrantel pamoate [A32282],[A32283],[L1893],[L1898]. … Pyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% pyrantel base [L1900].
Products: Pin-X, Pin XTideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawnIt is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.
Bromhexine
go.drugbank.com/drugs/DB09019ApprovedInvestigationalIt was introduced into the market in 1963, and is widely available as an over-the-counter drug in many countries. … It is derived from the Adhatoda vasica plant and aids in the clearance of excess mucus, improving breathing and reducing cough.
Mixtures: GLICERTOX N FSynonyms: N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine, 3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamineHydrocodone
go.drugbank.com/drugs/DB00956ApprovedIllicitInvestigationalHydrocodone is a synthetic opioid derivative of codeine.[T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain. … Hydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain.
Zenocutuzumab
go.drugbank.com/drugs/DB15559ApprovedInvestigational[L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma. … [A264833,A264843] Zenocutuzumab is also capable of promoting antibody-dependent cellular cytotoxicity in cancer cells.
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigationalElafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis. … [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878]
Norgestimate
go.drugbank.com/drugs/DB00957ApprovedInvestigationalNorgestimate was first described in the literature in 1977. … [A191068] It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat moderate acne vulgaris.
Synonyms: (17α)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime, (+)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one oxime acetate (ester)Vutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[A249010] The Val30Met variant is the most prevalent among hereditary ATTR patients with polyneuropathy, especially in Portugal, France, Sweden, and Japan. … [L42085] Another siRNA indicated for the treatment of polyneuropathy associated with hereditary ATTR is [patisiran].[A249010] Vutrisiran was approved by the FDA in June 2022.